Notably, if successful, the proposed strategy will be highly effective in the prevention of both MMR-proficient and MMR-deficient colorectal cancers; this is of importance because the MMR-deficient colorectal cancers pose a greater risk of resistance to DNA-alkylating drugs due to over-expression of MGMT or MMR-deficiency [27]–[29]. The gene discussed is MGMT; the disease is colorectal cancer.